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 I 
ABSTRACT 
Motor neuron disease (MND) is a heterogeneous family of neurodegenerative diseases, 
rare, characterized by an early involvement of motor neurons and can be hereditary or 
sporadic, including Amyotrophic lateral sclerosis (ALS) and X-linked spinal-bulbar 
muscular atrophy (SBMA).Three studies will be briefly presented below, with the aim 
of developing an understanding of psychological and neuropsychological aspects in 
these diseases.  
In Chapter 3 is presented a retrospective study with the aim to verify whether the 
presence of cognitive impairment in ALS patients (according to the classification 
proposed by Phukan et al., 2012) may have an impact on the degree of disease 
progression in terms of motor decline. Up to date, in literature the debate about the 
influence of cognitive impairment on survival in ALS patients is still ongoing and 
results are conflicting. In summary, after 6 or 12 months follow up we observed the 
same degree of disease progression both in patients with presence or absence of 
cognitive impairment. In Chapter 4 it is presented a pilot study with the aim to 
investigate the applicability and efficacy of a hypnotic treatment on the physical and 
psychological well-being perceived by ALS patients, considering also the indirect effect 
on the well-being on caregivers. ALS implies an inevitable and devastating 
psychological impact and this study represent, even if at a preliminary level, the first 
application of a protocol of psychological intervention with evidence of efficacy in ALS 
patients. In Chapter 6, it is presented a study with the aim to investigate the 
neuropsychological and psychological profile in patients with SBMA, poorly 
characterized in the recent literature. In summary, in contrast with the previous 
literature, executive functioning seems to be apparently preserved in patients with 
SBMA; nevertheless patients seem to have a specific dysfunction on the cognitive 
component of the Theory of Mind (ToM), while the affective component seems to be 
preserved.  
 
 
 II 
RIASSUNTO 
La Malattia del motoneurone (MND) è una famiglia eterogenea di malattie 
neurodegenerative, rare, caratterizzate da un precoce coinvolgimento dei motoneuroni e 
possono essere ereditarie o sporadiche, e includono tra le altre la Sclerosi laterale 
amiotrofica (SLA) e l’Atrofia muscolare spinobulbare (SBMA). Sono stati condotti tre 
studi, brevemente presentati di seguito, con l’obiettivo di sviluppare la comprensione 
degli aspetti psicologici e neuropsicologici nelle suddette malattie. 
Nel Capitolo 3 viene presentato uno studio retrospettivo con l’obiettivo di verificare se 
la presenza di deficit cognitivo in pazienti affetti da SLA (in accordo con la 
classificazione proposta da Phukan et al., 2012) possa avere un impatto sul grado di 
progressione di malattia in termini di declino motorio, ambito nel quale i dati presenti in 
letteratura sono contrastanti. In sintesi, a distanza di 6 o 12 mesi dal baseline  si osserva 
lo stesso grado di progressione di malattia sia in presenza sia in assenza del deficit 
cognitivo. Nel Capitolo 4 viene presentato uno studio pilota con l’obiettivo di indagare 
l’applicabilità e l’efficacia di un trattamento ipnotico sul benessere psicologico e fisico 
percepito dai pazienti, valutando inoltre l’effetto indiretto sul benessere dei familiari. 
Nonostante la SLA implichi un inevitabile e devastante impatto psicologico il presente 
studio rappresenterebbe, anche se a un livello preliminare, la prima applicazione di un 
protocollo di intervento psicologico con prove di efficacia in pazienti affetti da SLA. 
Nel Capitolo 6 viene presentato uno studio con l’obiettivo di indagare il profilo 
neuropsicologico e psicologico nei pazienti affetti da SBMA, ad oggi poco investigato 
con riferimento alla recente letteratura. In sintesi, a differenza degli studi presenti in 
letteratura, il funzionamento esecutivo sembra essere apparentemente preservato nei 
pazienti affetti da SBMA; ciononostante i pazienti sembrano avere una specifica 
disfunzione a carico della componente cognitiva della Teoria della Mente (ToM), 
mentre risulta preservata la componente affettiva.  
  
 
 
 
 
 
“Let us keep looking, in spite of everything. 
Let us keep searching. It is the best method of finding,  
and perhaps thanks to our efforts, 
the verdict we will give such a patient tomorrow  
will not be the same we must give this man today.” 
(Charcot, 1889) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
 
 
 
 
1 
 
Motor Neuron Disease 
 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
1.1 Introduction: definition of Motor Neuron Disease 
 
“Motor neuron disease” is usually used as an umbrella term for all those disorders 
involving selective loss of function of upper and/or lower motor neurons innervating 
the voluntary muscles of the limbs and bulbar regions [1].  
The term motor neuron disease encompasses:  
- combined upper and lower motor neuron disorders (as Amyotrophic lateral 
sclerosis), 
- pure lower motor neuron disorders (e.g. Hereditary bulbar palsy),  
- pure upper motor neuron disorders (e.g. Primary lateral sclerosis). 
A clinical classification of the different motor neuron disorders is represented in 
Table 1.1. 
In the following chapters we will focus our interest on two diseases: Amyotrophic 
lateral sclerosis and X-linked spinal and bulbar muscular atrophy.  
Amyotrophic lateral sclerosis (ALS), the most common presentation of Motor neuron 
disease, is a progressive disorder of unknown aetiology, that leads ultimately to death 
due to respiratory failure. There are other syndromes related to this spectrum of 
disorders including Progressive bulbar palsy (PBP), Progressive muscular atrophy 
(PMA), Primary lateral sclerosis (PLS), Flail arm syndrome (Vulpian-Bernhard 
syndrome), Flail leg syndrome (Pseudopolyneuritic form) and ALS with multi-
system involvement (e.g., ALS-Dementia) [2]. 
Spinal and Bulbar Muscular Atrophy (also known as Kennedy's syndrome) is a 
recessive adult-onset spinal muscular atrophy which, whilst involving anterior horn 
cells of the spinal cord and/or brainstem, has a more benign disease course than ALS 
[3-4]. It is an X-linked disorder due to a CAG trinucleotide repeat expansion in the 
androgen receptor gene (AR). As patients are frequently misdiagnosed, genetic 
testing is diagnostic for SBMA.  
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Table 1.1 Classification of Motor neuron disease (adapted from Donaghy, 1999) [1] 
Combined upper and lower motor neuron involvement 
Amyotrophic lateral sclerosis (Sporadic and familial forms) 
Pure lower motor neuron involvement 
Proximal hereditary motor neuronopathy 
X-linked spinal and bulbar muscular atrophy (Kennedy’s disease) 
Hexosaminidase deficiency 
Multifocal motor neuropathies 
Post polio syndrome 
Post-irradiation syndrome 
Monomelic, focal or segmental spinal muscular atrophy 
Pure upper motor neuron involvement 
Primary lateral sclerosis 
Hereditary spastic paraplegia 
Neurolathyrism 
Konzo 
 
1.2 References  
[1] Donaghy, M. (1999). Classification and clinical features of motor neurone 
diseases and motor neuropathies in adults. Journal of neurology, 246(5), 331-333. 
[2] Wijesekera, L. C., Mathers, S., Talman, P., Galtrey, C., Parkinson, M. H., 
Ganesalingam, J., ... & Leigh, P. N. (2009). Natural history and clinical features of 
the flail arm and flail leg ALS variants. Neurology, 72(12), 1087-1094. 
[3] Wijesekera, L. C., & Leigh, P. N. (2009). Amyotrophic lateral sclerosis. 
Orphanet journal of rare diseases, 4(1), 3. 
[4] Chahin, N., Klein, C., Mandrekar, J., & Sorenson, E. (2008). Natural history of 
spinal-bulbar muscular atrophy. Neurology, 70(21), 1967-1971.  
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2.1 Definition  
 
Amyotrophic Lateral Sclerosis (ALS) is a disease known in the world by different 
terminologies: Charcot's disease (named after the French neurologist who first described 
it in the 19th century); Lou Gehrig's disease (preferred in the United States), eponym 
for ALS used after the baseball player that in 1939 raised public attention on the 
disease; Motor neuron disease (MND - used in the U.K.);  SLA-sclérose latérale 
amyotrophique (term Charcot gave the disease, is used in France).  
Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder involving 
primarily motor neurons in the cerebral cortex, brainstem and spinal cord [1]. 
Moreover, about half patients show cognitive and behavioural impairments in 
addition to motor decline; while a subgroup of patients develop a frontotemporal 
dementia [2].  
Specifically, the term "Amyotrophy" means the atrophy of muscle fibres, which are 
denervated as their corresponding anterior horn cells degenerate, leading to weakness 
of affected muscles and visible fasciculations. "Lateral sclerosis" describes the 
hardening of the anterior and lateral corticospinal tracts as motor neurons in these 
areas degenerate and are replaced by gliosis [3].  
The loss of upper (UMN) and lower (LMN) motor neurons contribute in a different 
measure for each individual to the patient's symptoms and signs. 
The cause of ALS is unknown although some genetic risk factors have been 
identified. The etiology is sporadic (sALS) in the majority of cases, although familial 
forms (fALS) account for about 10% and are mainly transmitted by an autosomal 
dominant inheritance [4]. Sporadic ALS is thought to have both genetic and 
environmental influences, but the main causes have yet to be discovered [5]. 
To the present day, Amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) share common genetic, pathological, and clinical features. It 
suggests that ALS and FTD are two ends of a possible spectrum of one disease [6] 
(Figure 2.1). 
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Genetic variants in the ALS/FTD spectrum including C9orf72 repeat expansions, 
SOD1, TDP-43, and FUS mutations are found in familial as well as sporadic patients 
diagnosed with either of these neurological disorders [7].  
 
 
 
 
Figure 2.1. ALS/FTD spectrum (adapted by Robberecht and Philips, 2013 [6]) 
 
 
2.2 Epidemiology 
 
Amyotrophic lateral sclerosis is a rare disease.  In a recent study [8] has been 
reported a mean incidence of disease range from 1.8 to 2.8/100,000 (respectively in 
North America and in Europe), while the mean prevalence range goes from 3.40 to 
5.40/100,000 (in North America and in Europe). 
In the last 25 years there has been an increased incidence which could be partly 
explained by the constant increase in the average lifespan of  Italian population and 
its aging as much as by an improved diagnostic assessment [9], especially in women 
and the elderly who nowadays resort to medical attention much more often than in 
the past [10].  
In Europe, ALS is more common in men than in women by a ratio of 1.2-1.5:1, 
which may be due to protective-hormones in women [11]. This disparity is largely 
attributable to the increased frequency of spinal-onset ALS in men and bulbar onset 
is more common in women and in older adults [12].  
Median survival is of 3-5 years from first symptom and generally death overcomes 
with a respiratory failure; only 5-10% of patients survive beyond 10 years [13-14]. 
Age onset in sporadic ALS (about 90% of ALS patients) is between 58-63 years, 
while in familial ALS (about 5-10% of ALS patients) is between 47-52 years [15]. 
ALS FTLD ALS-Ci/Bi FTLD-MND ALS-FTLD 
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2.3 Clinical features: symptomatology, diagnosis, phenotypes, therapy and 
multidisciplinary care 
 
The clinical feature of ALS is the simultaneous presence of clinical signs of 
involvement of the upper (UMN) and lower motor neuron (LMN), although the 
practice has revealed the existence of a large diversity of presentation of the disease. 
 
Symptomatology 
 
Loss of LMNs causes fasciculation, cramps, muscle atrophy and marked weakness, 
which is often more disabling for patients than the spasticity, hyperreflexia and 
modest weakness associated with UMN disease. 
Babinski and Hoffman signs along with emotional lability are also characteristic 
findings of UMN degeneration. 
In particular, emotional lability occurs at least in 50% of patients with ALS 
irrespective of the presence or absence of bulbar motor signs [16] and it does not 
correlate with cognitive impairment [17]. Extraocular movements, bladder and bowel 
function and sensation are spared. 
In two-third of patients ALS begins in the limbs, more often in the arms. Initial 
symptoms are usually unilateral and focal. Patients may incur in loss of hand 
dexterity, weakness when lifting the arms or difficulty in walking.  
If ALS begins with a bulbar-onset instead, tongue atrophies and fasciculates. The 
first symptom is more often dysarthria (a motor speech disorder), which may further 
degenerate into sialorrhea (excessive salivation), malnutrition and anarthria (loss of 
articulate speech) 
Disease progression in ALS patients differs considerably between individuals [18-
20], but progressive functional decline ultimately leads to a complete loss of 
independence.  
Cognitive impairment in patients with ALS was first described in the 19th century. 
Consensus criteria have been proposed to categorize various forms of cognitive and 
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behavioural impairment [2]. Moreover, depression and anxiety may occur during any 
stage of the disease. When patients feel this emotional symptoms they perceive a 
poorer quality of life because of a loss of sleep and appetite [21]. 
Neuropsychological and psychological aspects will be discussed in detail in the next 
chapters.  
 
Diagnosis  
 
Despite the advances of investigative medicine over the past century, there is no 
definitive test for ALS diagnosis, but it is established excluding other causes of 
progressive upper motor neuron and/or lower motor neuron dysfunction. 
To aid in diagnosis and classify patients for research studies, experts (WFN, World 
Federation of Neurology Research Group on Motor Neuron Diseases) developed in 1994 
the “El Escorial” diagnostic criteria and in 2000 the revised “Airlie House” criteria 
[1], shown in Table 2.1. 
Using these criteria patients can be classified into four categories: ‘Clinically 
definite’, ‘Clinically probable’, ‘Clinically probable-Laboratory supported’ and 
‘Clinically possible’ [22]. 
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Phenotypes 
 
Disease phenotype is generally classified by the onset disease (spinal or bulbar), but 
further phenotypic subclassification is based on the degree of upper and lower motor 
neuron involvement (Figure 2.2). ALS occurs with the simultaneous involvement of 
the upper and lower motor neuron. Other forms include the involvement of a single 
motor neuron (upper or lower); while progressive bulbar palsy is characterized by the 
degeneration of the lower portion of the brain stem. Description of ALS phenotypes 
will be better illustrated in Table 2.2: primary lateral sclerosis (PLS), progressive 
muscular atrophy (PMA) and progressive bulbar palsy (PBP) [4].  
 
 14 
 
Figure 2.2. Types of onset in Amyotrophic lateral sclerosis (ALS) 
 
Table 2.2. ALS and related phenotypes 
Disease Clinical features Comments Median survival 
ALS Multiple spinal 
segments affected with 
both upper and lower 
motor neuron signs 
Most common adult-onset 
form of motor neuron 
disease 
3-5 years 
Primary lateral 
sclerosis 
Upper motor neuron 
signs only 
Many patients eventully 
develop clinical or 
electrophysiological signs of 
lower motor neuron 
involvment: ALS develops 
in up to 77% of patients 
within 3-4 years 
≥20 years for patients 
who do not progress to 
ALS 
Progressive 
muscular 
atrophy 
Lower motor neuron 
signs only 
Variable evolution in ALS Typically 5 years, but a 
subset survive for ≥20 
years 
Progressive 
bulbar palsy 
Speech and swallowing 
initially affected, owing 
to lower motor neuron 
involvment of cranial 
nerves IX, X and XII 
Symptoms include 
dysarthria, dysphagia and 
dysphonia; aspiration 
pneumonia is usually the 
cause of death 
2-3 years 
Abbrevation: ALS, Amyotrophic lateral sclerosis 
(Table adapted by Hardiman et al., 2011 [4]) 
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However, these three phenotypic categories do not fully capture the spectrum of 
clinical heterogeneity in ALS. Since the late 19th and early 20th centuries two other 
forms have been recognized: the flail arm (FA) and flail leg (FL) syndromes. The FA 
syndrome is a LMN disorder of upper limbs and it is characterized predominantly by 
progressive proximal weakness and wasting: it may remain relatively confined for a 
prolonged period, resulting in a man-in-the-barrel appearance. The FL syndrome is a 
LMN disorder of lower limbs characterized by progressive distal onset weakness and 
wasting. It presents a slower disease progression [23].  
The variability of phenotypes and overall rapid progression of the disease make 
difficult to predict survival time or timing of interventions. Generally, longer survival 
is associated with limb-onset, younger age, better motor function, higher breathing 
capacity, stable weight, and longer interval between symptom onset and diagnosis 
[24]. 
The ‘flail arm’ and ‘flail leg’ syndromes have a significantly better survival than 
Amyotrophic lateral sclerosis (ALS) or progressive muscular atrophy (PMA) cases 
that are not classified as FA or FL [23].  
 
Therapy and multidisciplinary care 
 
Following diagnosis, management of patients with ALS is centred on a combination 
of neuroprotective medication, multidisciplinary clinics to reduce symptoms 
(sialorrhoea, emotional lability, cramps, spasticity and pain) and aids for improving 
personal autonomy, movement and communication. Up to date there is no therapy 
able to cure ALS, but Riluzole (licensed in 1996) is the only drug approved which 
can slow the progression of the disease and prolong survival for approximately three 
months [25]. In advances stage of ALS inadequate nutrition  becomes common and 
when respiratory muscle becomes weak it develops symptoms of dyspnea, daytime 
fatigue and morning headaches. Recent guidelines highlight that percutaneous 
endoscopic gastrostomy feeding improves nutrition and quality of life, and 
gastrostomy tubes should be placed before the development of respiratory 
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insufficiency. Non-invasive positive-pressure ventilation also improves survival and 
quality of life. However, advance directives for palliative end-of-life care should be 
discussed early with the patient and carers, respecting the patients social and cultural 
background. The purpose of palliative care is to maximize the quality of life of 
patients and families by relieving symptoms, providing emotional, psychological and 
spiritual support as needed, removing obstacles to a peaceful death and supporting 
the family in bereavement [26]. Attendance at multidisciplinary clinics may extend 
survival, decrease medical complications and improve quality of life [16]. 
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have an impact on disease progression? 
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3.1 Cognitive functioning, progression disease and survival: an overview 
 
Cognitive functioning 
 
Although motor system deficits are prominent in Amyotrophic lateral sclerosis 
(ALS), this multisystem disorder is also accompanied by cognitive changes, more or 
less subtle.  
Cognitive deficits might initially have a subtle appearance and are often overlooked, 
but thanks to an appropriate neuropsychological assessment it has been estimated 
that  cognitive impairment may occur in more than 40% of incident patients with 
ALS and 10-15% may meet criteria for diagnosis of frontotemporal dementia-FTDL 
[1-2]. The three variants of FTDL are defined by consensus criteria proposed in 1998 
by Neary and colleagues [3] (Table 3.1).  
 
 
Table 3.1 Variant of frontotemporal lobar dementia 
(proposed by Neary et al., 1998; adapted by Phukan et al., 2007) [3-4] 
 
Neuropathological 
topografy 
Cognitive symptoms Behavioural changes Neurological findings 
Frontal 
variant 
frontotempor
al dementia 
Frontal atrophy more 
severe than temporal 
atrophy. Particularly 
affected right dorsolateral 
and prefrontal cortex, and 
left premotor cortex 
Executive dysfunction  (eg., 
verbal fluency and attention) 
Distractibility, disinhibition, 
decline in personal hygiene, 
hyperorality, compulsions, 
perseveration, apathy and 
submissiveness 
Frontal release signs and primitive 
reflexes, motor neuron disease, 
and possible extrapyramidal 
features (Progressive 
Supranuclear Palsy or 
Corticobasal Degeneration) 
Non-fluent 
progressive 
aphasia 
Asymmetric atrophy of 
left hemisphere. 
Particularly affected: left 
frontal, insular, anterior 
parietal, superior 
temporal, and perisylvian 
cortex 
A disorder of expressive 
language. Non-fluent 
spotaneous speech with 
agrammatism, phonemic 
paraphasias, and anomia. 
Impaired executive function 
and working memory 
Behavioural changes are 
typically seen late in the course 
of this illness. Possible social 
withdrawal and depression 
Supranuclear gaze disturbance, 
axial rigidity, alien limb, and focal 
dystonias 
Semantic 
dementia 
Temporal atrophy more 
severe than frontal 
atrophy. Particularly 
affected: insula, amygdala, 
and anterior hippocampus 
Impaired understanding of 
word meaning and object 
identity, fluent but empty 
spontaneous speech, semantic 
paraphasias, long-term memory 
loss, and perceptual disorder 
(eg. prosopagnosia, associative 
agnosia or both) 
Emotional withdrawal, 
depression, mental rigidity, and 
compulsions 
Neurological findings emerge late 
in the course of this illness 
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The variant most frequently described in ALS-patients is frontal variant 
frontotemporal dementia (fvFTD); the other two variants are non-fluent progressive 
aphasia which is characterized by language impairment and semantic dementia, 
which is characterized by a loss of conceptual knowledge [4]. 
Strong and colleagues in 2009 [5] proposed the following classification system (see 
Table 3.2 for much details) for the frontotemporal syndromes in ALS: cognitively 
impaired (ALSci), behaviourally impaired (ALSbi), ALS-Frontotemporal dementia 
(ALS-FTD)  in which Neary criteria for FTD are met, FTD-MND like in which 
patients clinically had FTD and pathologically have motor neuron loss but did not 
manifest signs of motor neuron disease during life and ALS-Dementia in which 
patients have Alzheimer’s or vascular dementia [6].  
 
Table 3.2 Classification system for the frontotemporal syndromes in ALS  
                (adapted by Strong et al., 2009) [5] 
Axis II. Cognitive/behavioural characterization - Frontotemporal lobar degeneration with ALS 
Heading Subheading Existing, synonymous 
term in the literature 
Characteristics 
ALS-FTD ALS-bvFTD 
ALS-PNFA 
ALS-SD 
ALS-Dementia (ALS-D), FTD-
MND 
ALS patient meeting Neary criteria for FTD 
ALS patient meeting Neary criteria for PNFA 
ALS patient meeting Neary criteria for SD 
ALSbi 
  
ALS patient meeting at least 2 non-overlapping supportive 
diagnostic features from Neary criteria for FTD 
ALSci 
  
Evidence of cognitive impairment at or below the 5° 
percentile on at least 2 distinctive tests of cognition that are 
sensitive for executive functioning 
FTD-MND-like 
  
A neuropathological diagnosis in which FTLD is the 
primary diagnosis but in which there is neuropathological 
evidence of motor neuron degeneration, but insufficient to 
be classified as ALS 
ALS-dementia ALS-AD 
ALS-vascular 
dementia 
ALS-mixed dementia 
ALS-dementia (ALS-D) ALS with dementia, not typical of FTLD 
ALS in association with AD 
ALS in association with vascular dementia 
ALS in association with a mixed dementia (eg. AD-vascular 
dementia) 
ALS-Parkinsonism-
dementia complex 
 
Western Pacific variant of ALS ALS concurrent with dementia and/or Parkinsonism 
occurring in hyperendemic foci of the western Pacific 
 
In non-demented ALS patients cognitive functioning is not an universal feature, 
while executive dysfunction is predominant. Executive functions, traditionally 
thought of as higher-level mental processes that control and organise other cognitive 
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processes [7], are a heterogeneous set of skills that facilitate problem solving and 
responses to novelty. They are also implicated in behavioural regulation, response 
initiation, motivation and elements of memory functioning [8].  
Recently a three domain-based classification was proposed suggesting that ALS with 
cognitive impairment is a heterogenous disease [2]: 1. Impairment in executive 
dysfunction (ALS-Ex); 2. Non-executive cognitive impairment (ALS-NECI); 3. No 
cognitive impairment. The criteria used by Phukan and colleagues (2012) [2] to 
define dysfunction in each cognitive domain is shown in Table 3.3.  
 
Table 3.3 Cognitive domain-based categorization for non-demented ALS patients  
                   proposed by Phukan et al., 2012 [2] 
COGNITIVE GROUPS COGNITIVE DOMAIN 
1. ALS-Ex Impairment in executive dysfunction (ALS-Ex) single domain 
or in association with impairment in other cognitive domains 
(multidomain) 
2. ALS-NECI Non-executive cognitive impairment (ALS-NECI), single 
domain (eg. Language only) or multidomain dysfunction (eg. 
Language and memory) 
3. No cognitive impairment 
 
A similar approach has been adopted in a recent study conducted in Italy [9], where a 
different degree of cognitive impairment has been observed in about 50% of ALS 
patients. The authors suggested a possible role of cognitive reserve in ALS-related 
cognitive impairment, corroborated by some studies showing that a lower 
educational level and bulbar onset associate with cognitive involvement [10].  
Cognitive decline appears to be influenced by cognition at baseline, in particular 
ALS patients with normal cognition at baseline showed a tendency to remain 
cognitively intact with a slower motor and cognitive progression, while ALS patients 
with cognitive impairment have been associated with a more rapid cognitive decline 
[11].  
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Rate of disease progression 
 
Phenotypic variability in ALS complicates measurements of disease progression that 
differs considerably between individuals [12-14]. In an individual with ALS, disease 
advances at a relatively constant rate, although progression may be influenced by 
clinical, demographic and genetic features [12]. 
Ultimately, progressive functional decline leads to a complete loss of independence.  
In literature the debate about the influence of cognitive impairment on survival in 
ALS patients is still ongoing and results are conflicting.  
Some authors suggest that cognitive performance was not related to survival [15] or 
that demented and non-demented ALS patients did not differ in disease duration [16], 
while some others reply that faster rates of motor functional decline have been 
observed in ALS patients with cognitive impairment in executive function at baseline 
[11]. 
 
Survival 
 
In ALS patients the time to death or tracheostomy, in clinical trials, is generally used 
to define survival. Median survival is of 3-5 years from first symptom and generally 
death overcomes with a respiratory failure; only 5-10% of patients survive beyond 10 
years [17-18]. Previous studies of ALS populations identified several negative 
prognostic factors, including older age at onset and bulbar onset [17-19]. 
Furthermore, Elamin and colleagues (2011) [20] suggested that executive 
dysfunction is a negative prognostic indicator. In particular, ALS-FTD patients and 
patients with executive dysfunction have shorter survival time than any other 
cognitive group [9,20], regardless of the limb or bulbar onset [4,21].  
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3.1 Aim of study 
 
Recent studies have shown that ALS patients with cognitive impairment in executive 
functioning have a shorter survival than patients with cognitive impairment in other 
domains or the ones cognitively intact: hence the need to identify whether cognitive 
impairment may have a different impact on degree of disease progression or if a 
shorter survival can be associated to poor compliance with medical intervention [21]. 
The study aims to determine if the presence of cognitive impairments has an impact 
on disease progression, in terms of motor decline. Disease progression was assessed 
using the ALS-MITOS system (ALS Milano-Torino Staging) [22], a new tool that 
captures the loss of functions based on subscores of the ALSFRS-R (revised ALS 
Functional Rating Scale) [23]. 
 
3.2 Methods: participants and measures 
 
ALS patients recruitment has been based on the patients group who has participated 
in a previous retrospective study [24], as shown in Figure 3.1. Cognitive profile has 
been assessed with an extensive neuropsychological battery, at the first visit after 
diagnosis. Performance of these 165 sporadic ALS patients, without diagnosis of 
FTD or other frank dementia, was compared with the one obtained by 134 healthy 
volunteers (HCs). HCs was matched with patients group regarding age, sex and 
educational level. 
 
Figure 3.1 Flow chart of patients included in analysis. ALS. Amyotrophic lateral sclerosis 
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Palmieri and colleagues (2014) [24] categorised all 165 patients into three cognitive 
subgroups, according to the recent classification suggested by Phukan and colleagues 
(2012) [2]:  
- Impairment in executive dysfunction (ALS-Ex): patients (n=47; 28.5% of 
total) with executive impairment in single domain of executive functioning or 
in association with impairment in other cognitive domain.   
- Non-executive cognitive impairment (ALS-NECI): patients (n=30; 18.2% of 
total) with non-executive cognitive impairment, but impairment in other 
single or multiple cognitive domains (e.g. memory and language functioning, 
visuospatial abilities, nonlogic reasoning).  
- ALS-No cognitive impairment: patients (n=88; the remaining 53.3%) without 
apparent cognitive impairment.  
 
Participants: Demographic and clinical characteristics 
 
ALS patients referred to Motor Neuron Disease Centre of Padua University Hospital 
from 2006 to 2010 with  a diagnosis of possible, probable or definite ALS according 
to Revised El Escorial Criteria [25].  
Exclusion criteria include diagnosis of FTD or other kinds of dementia, history of 
previous neurological conditions that could affect cognition (e.g. brain stroke or 
traumatic brain injury), permanent active ventilation, psychiatric diseases (such as 
depression or alcoholism) and the use of high-dose of psychoactive medications.  
Cognitive profile has been defined by performance to tests of a comprehensive 
neuropsychological battery, which it has been administered to patients at the time of 
the first visit after diagnosis.  
Degree of disease was assessed at baseline (T0) and then at 6-month intervals (T1 
and T2) only for 72 of 165 sporadic ALS patients (37 males and 35 females). These 
participants have a mean age of 63.06 years (SD = 7.87; age range = 45-81). To 
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study the effect of cognitive status on disease progression, we operationally 
classified the participants into three cognitive subgroups (ALS-Ex, ALS-NECI and 
ALS-No cognitive impairment, Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Percent of ALS patients into the three cognitive subgroups. 
 
 
 
To check whether there were statistically significant differences between cognitive 
groups in age, educational level (years), time since ALS onset (months), site of onset 
and ALSFRS-R score the Kruskal-Wallis test was performed. The result of the 
nonparametric test indicates that the differences are statistically significant in gender 
(X2(2)=8.31,p=0.02), age (X2(2)=16.23,p≤0.001) and educational level (X(2)=16.23, 
p=0.002), but there were no statistically differences in time since ALS onset, site of 
onset and ALSFRS-R score at baseline. Demographic and clinical details are shown 
in Table 3.4.  
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 Measures: neuropsychological assessment 
 
Neuropsychological assessment, lasting approximately an hour, consisted in 
standardized neuropsychological instruments and it encompassed mainly executive 
function and also non-executive cognitive domains such as memory and language 
functions. The available literature suggests early involvement of frontally-mediated 
executive functions in ALS patients and verbal fluency is a sensitive and reliable test 
of executive functioning.  
The majority of tests were not timed, and when it was expected, the score was 
corrected considering bulbar and/or motor patient's disability in time-dependent 
tasks. 
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The neuropsychological battery [24] included tests to evaluate: 
a. executive functions  
- the Phonemic Verbal Fluency Test (PVFT), in accordance to Abrahams’ 
protocol [26] has been considered F index (a measure of the average time 
taken to think of each word) to control individual variations as consequence 
of dysarthria, 
- the Abrahams M and C Written Verbal Fluency Tests (AWVFT), M and C 
indexes have been used to control motor impairment, 
- the Modified Wisconsin Cards Sorting Test (M-WCST),  
- the Trial Making Test (TMT) A e B direct score, number of error and the 
TMT B-A derived score, in accordance with Reitan’s protocol [27]. 
b. long-term and short-term memories 
- the Prose Memory Test (PMT), considering recency and latency effects. 
- the Digit Span Forward (DSFT) and the Backward (DSBT), 
- the Dysillabic Word Test (DWT). 
c. language 
- the Semantic Verbal Fluency Test (SVFT), in accordance to Abrahams’ 
protocol [26] has been considered S index, 
- the Boston Naming Tests (BNT), considering total number of errors, 
semantic and phonemic cues. 
- the Token Test (TT). 
d. non-verbal logic reasoning 
- the Raven’s Coloured Progressive Matrices (RsCPM). 
e. visuospatial abilities 
- the Rey-Osterrieth Complex Figure Test (ROCFT), considering copy and 
recall performance.  
Healthy controls underwent the same neuropsychological battery.  
Abnormal performance on any test was defined as a score that is 2 SD below the 
mean for HCs. Executive dysfunction was defined as abnormal performance on at 
least two executive tests. Non-executive cognitive impairment was defined by 
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abnormal performance on at least four parameters in memory, language or visuo-
spatial functions. Further, mood tone was assessed using the Beck Depression 
Inventory [28].  
 
Measures: neurological assessment 
 
Neurologist with extensive clinical experience about the disease assessed motor 
functional decline using the following tool: the revised ALS Functional Rating Scale 
(ALSFRS-R, Panel 3.1): a scale that measures fine and gross motor tasks, bulbar 
functions and respiratory functions in ALS patients [23]. It is composed by 12 items 
and the maximum score is 48.   
The ALSFRS-R is a useful outcome measure in therapeutic trials [23] and it is a 
known predictor of progression and survival in ALS patients [29]. Recently Chiò and 
colleagues (2015) [22] proposed an ALS staging system (ALS Milano-Torino 
Staging, MITOS) to measure the progression of ALS and to overcome the intrinsic 
limitations of the ALSFRS-R including: (a) non-linear, thus prone to biases; (b) 
multidimensional, thus unfit as single score and unable to satisfy rigorous 
measurement standards; (c) floor-effect, thus unable to capture late-stage clinical 
changes. 
This ALS staging system was also recently validated [30] and it can reliably predict 
the course of ALS up to 18 months.  
Specifically, the ALS-MITOS system [22] is based on four functional domains of the 
ALSFRS-R: movement (walking or self-care), swallowing, communicating (speech 
and handwriting) and breathing (dyspnoea or respiratory insufficiency), as shown in 
Table 3.5. Each domain has a threshold focusing on loss of function in the specific 
ALSFRS-R subscores. Values of 0 or 1 (respectively below or above threshold) were 
assigned and the stages were determined by the sum of functional score of 1 for each 
domain. Stage 0 correspond with none loss of function, while Stage 5 coincide with 
loss of five functional domains (death). For ALS-MITOS the cut-off to predict 
survival at 12 and 18 months correspond to 1 (loss of at least one function).  
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Panel 3.1 Amyotrophic lateral sclerosis functional rating scale - revised [23]  
1. Speech 
     4 Normal speech  
     3 Detectable disturbance 
     2 Intelligible without repeating 
     1 Speech with non-verbal communication 
     0 Loss of useful speech 
2. Salivation 
     4 Normal  
     3 Slight, but definite excess of saliva 
     2 Moderate excessive of saliva, minimum drooling 
     1 Marked excessive of saliva, some drooling 
     0 Marked drooling, needs constant tissue 
3. Swallowing 
     4 Normal eating habits 
     3 Early eating problems, occasional choking 
     2 Dietary consistency changes 
     1 Needs supplemental tube feeding 
     0 Nil orally 
4. Handwriting 
     4 Normal  
     3 Slow or sloppy, all words legible 
     2 Not all word legible 
     1 Able to grip pen, but cannot write 
     0 Unable to grip pen 
5. Cutting food and handling utensils 
     4 Normal  
     3 Slow and clumsy, but no help needed 
     2 Can cut most food, although clumsy and needs some help 
     1 Food must be cut by someone else 
     0 Needs to be fed 
6. Dressing and hygiene 
     4 Normal  
     3 Independent, but decreased efficiency 
     2 Some help with closures and fasteners 
     1 Provides minimum assistance to caregiver 
     0 Unable to perform any task 
7. Turning in bed 
     4 Normal 
     3 Slow and clumsy 
     2 Can turn alone with difficulty 
     1 Can initiate but cannot turn or adjust sheets 
     0 Total dependence 
8. Walking 
     4 Normal  
     3 Early ambulation difficulties 
     2 Walks with assistance 
     1 Non-ambulatory, functional movement 
     0 No purposeful leg movement 
9. Climbing stairs 
     4 Normal   
     3 Slow 
     2 Mild unsteadiness or fatigue 
     1 Needs assistance  
     0 Cannot do 
10. Dyspnoea 
     4 None 
     3 Occurs when walking 
     2 Occurs when eating, bathing, or dressing 
     1 Occurs at rest 
     0 Considerable difficulty 
11. Orthopnoea 
     4 None 
     3 Some difficulty, does not routinely use more than two pillows 
     2 Needs extra pillows to sleep 
     1 Only sleeps sitting up 
     0 Unable to sleep 
12. Respiratory isufficiency 
     4 None  
     3 Intermittent use of non-invasive ventilation 
     2 Continuous use of non-invasive ventilation at night 
     1 Continuous use of non-invasive ventilation, day and night 
     0 Mechanical ventilation via tracheostomy 
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Table 3.5 ALS-MITOS Functional domains and stages [22] 
ALSFRS-R domain Functional score 
Movement                 Walking or 0/1 
                                     Self-care 0/1 
Swallowing                Swallowing 0/1 
Communicating        Speech and 0/1 
                                     Handwriting  0/1 
Breathing                   Dispnea or 0/1 
                                     Respiratory    
                                       insufficiency 
0/1 
ALS-MITOS  
Stage Functional domains lost 
0 None 
1 1 domain 
2  2 domains 
3  3 domains 
4  4 domains 
5 Death 
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3.4 Statistical analyses 
 
Data analysis were carried out using SPSS (Chicago, IL). The Kruskal-Wallis test 
was performed to check whether there were statistically significant differences 
between cognitive subgroups in age, educational level (years), time since ALS onset 
(months), site of onset and ALSFRS-R score, as detailed above (pgg. 27-28). 
The ALS-MITOS system was calculated for each patient at baseline and then at 6-
month intervals (T1 and T2). The distribution of ALS stage was examined using 
descriptive statistics. The X2 test was performed to verify the presence of significant 
differences in ALS-MITOS stages between  the three cognitive subgroups.   
 
3.5 Results 
 
The analysis of progression based on the ALS-MITOS system was performed 
between the three cognitive subgroups. At baseline, among the ALS-Ex group 16 
patients (80%) were in Stage 0 and 4 patients (20%) were in Stage 1 and none in 
other Stages. 
In ALS-NECI group 11 patients (73.3%) were in Stage 0 and 4 patients (26.7%) 
were in Stage 1. In ALS-No cognitive impairment group 32 patients (86.5%) were in 
Stage 0 and the remaining 5 patients (13.5%) were in Stage 1. In the three cognitive 
subgroups, all patients in Stage 1 had lost function in movement (walking/self-care) 
and details are shown in Figure 3.3a.   
At 6-month follow up, patients that remained in Stage 0 were 13 (65%) of ALS-Ex, 9 
(60%) of ALS-NECI and 22 patients (59.5%) cognitively intact. The other patients 
were in Stage 1 and only 2 patients cognitively intact progressed to advances stages 
of disease (Stage 2 and Stage 3).  
At 12 months, only 1 ALS-Ex patient (5%) progressed to Stage 2. 
In ALS-NECI group 2 patients (13.3%) were in Stage 2 and 1 patient was in Stage 4. 
Among the ALS patients cognitively intact, 5 patients (13.5%) were in Stage 2, 4 
patients (10.8%) were in Stage 3 and 2 patients (5.4%) progressed to Stage 4.  
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The results of the X2 test do not reveal significant differences in the progression of 
disease between the cognitive subgroups at baseline and at 6-12 months (Figure 3.3).  
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Figure 3.3. ALS stage at baseline (a), at 6 months (b) and at 12 months (c) in the three cognitive subgroups.  
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3.6 Discussion 
 
In literature the debate of the effect of cognitive impairment on survival in ALS 
patients is still ongoing and results are conflicting. The present study aimed to reveal 
whether cognitive impairment may have a different impact on degree of disease 
progression or if a shorter survival can be associated to poor compliance with 
medical intervention [21].  
We examined disease progression, in term of motor decline, using ALS-MITOS 
system, a novel tool that was recently validated [30] and overcomes limitations of 
ALSFRS-R.  
This stage system is based on the unidirectional progression of function in four key 
domains (movement, swallowing, communicating and breathing), the attainment of 
which means their loss without any possibility to recover.  
Our findings have demonstrated that cognitive impairment does not have any 
influence on disease progression, because at 6-12 month intervals the rate of 
progression was similar between the three cognitive subgroups. Specifically, patients 
lost the same functions (walking/self-care) at baseline and showed a similar 
progression in reaching the following stages.  
This results corroborates the recent studies [20-21] which don’t rule out the chance 
that  survival rate of ALS affected patient with a cognitive impairments resulting 
statistically lower  is not related to a more aggressive form of disease as much as 
their poor compliance with medical intervention, like not-invasive ventilation (NIV) 
and/or enteral nutrition (NE, PEG).  
The main limitation of our study was the small sample size within the three cognitive 
subgroups because clinical assessment was not available for all the initial 165 
patients at 6-12 months follow up, but this is a natural consequence of a retrospective 
study design. Despite this, our findings determine that at 6 and 12 months follow-up 
presence of cognitive impairments does not have an impact on disease progression, 
in terms of different rate of motor decline, indicating that shorter survival of ALS 
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patients with executive dysfunction, which is reported in other studies [20-21], is not 
explained by progression rate of their disease progression (in term of motor decline).  
Future research in this field should investigate specifically the relationship between 
the different degrees of cognitive impairment and patient’s compliance in the use of 
medical interventions aids.  
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4.1 Psychological aspects of ALS patients and caregivers: an overview 
 
People with Amyotrophic Lateral Sclerosis (ALS) experience a huge amount of 
continuous emotional distress. From breaking the news to the rapid motor decline, 
which causes physical dependence even in activities of daily living, the patient and 
his caregiver are exposed to complex emotional reactions.  
The Constitution of the World Health Organization (WHO) defines health as “a state 
of complete physical, mental, and social well-being not merely the absence of 
disease or infirmity”. It follows that the measurement of health and the effects of 
health care must include not only an indication of changes in the frequency and 
severity of diseases but also an estimation of well-being and quality of life, 
regardless of the physical status of person [2]. 
WHO defines quality of life as “a broad ranging concept affected in a complex way 
by the person’s physical health, psychological state, level of independence, social 
relationships, personal beliefs and their relationship to salient features of their 
environment” [3].  
Some studies have shown the relative independence of the degree of disability on the 
quality of life perceived by patients with ALS [4-6]. Psychological well-being seems 
to be more important in maintaining the perceived quality of life, than the degree of 
impairment of physical aspects [7]. Impact of disease on emotional well-being differs 
greatly between individuals, and the psychological reaction of patients to their 
disease, and their ability to cope with it have an effect on disease’s evolution itself 
[8-10]. Psychological well-being seems to be also crucial in determining a better 
prognosis in patients with ALS [11]. Disease affects not only the patient, but also his 
relatives, who face harsh emotional challenges that interact with those of the patient 
[12-13]: there would seem to be a relationship between well-being perceived by the 
patient and the one  perceived by his relatives [14]. Depression and anxiety typically 
occurs in response to the disease, especially in the first phase, in which patients 
experience anger, hopelessness and suicidal ideation [15-16]. The psychological 
status of patient seems to be directly related to their caregiver’s one [13,17-18]. 
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Likewise, the psychological status of the caregiver appears to have a profound 
impact on the patient [19].  
 
4.2 Aim of study 
 
Psychological issues in the Amyotrophic lateral sclerosis’ (ALS) field have been 
relatively well studied, considering the low prevalence of the illness, but as recently 
emphasized by Pagnini (2013) [16] there is an absence of research on efficacy of 
psychological interventions in ALS: hence the need to investigate the effect of 
hypnosis-based intervention on psychological and perceived physical well-being in 
patients and the indirect effect on caregivers.  
 
4.3 Methods 
 
For this pilot study were recruited eight (50% females) volunteers patients (mean 
age=55, SD=7.14) referred to Motor Neuron Disease Clinic in Padua with a 
diagnosis of possible, probable or definite ALS according to Revised El Escorial 
Criteria [20] and their respective caregivers. They underwent Neurological and 
neuropsychological assessment within a week before the first treatment session. 
ALSFRS-R [21] mean score was 35 (SD=7.1, range: 21-42). Patients’ 
neuropsychological profiles did not reveal any abnormal performance if compared to 
normative data.  
At pre and post treatment phase anxiety and depression levels in patients and their 
caregivers were measured with the Hospital Anxiety and Depression Scale (HADS) 
[22]. This questionnaire is composed of an Anxiety subscale and a Depression 
subscale. Quality of life was assessed with the Amyotrophic Lateral Sclerosis 
Specific Quality of Life-revised (ALSSQOL-r) [23-24] and the ALS Assessment 
Questionnaire (ALSAQ-5 derived from the broader ALSAQ-40) [25-26].  
However, global satisfaction with hypnotic-based treatment and perceived physical 
symptoms’ changes were qualitatively investigated in patients. 
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The hypnosis intervention and self-hypnosis training protocol lasted 1 month with 
domiciliary sessions. The general induction was recorded in a CD audio which was 
left to each patients to practice at least once a day. This procedure was common for 
all patient and for all treatment phases and it is inspired by Jensen and colleagues 
(2009, 2011) [27-28] hypnosis-based protocol, also applied with success on patients 
with multiple sclerosis.  
 
4.4 Data analysis  
 
All analyses were carried out with R software, version 2.15.1. Non-parametric 
statistics were preferred because of small samples’ size where it is not safe to assume 
a normal distribution.  
 
4.5 Results 
 
Patients declared to have successfully practiced self-hypnosis at least once every day 
in the great majority of the days during the treatment. Data analysis revealed the 
efficacy of the psychological intervention protocol on patients with ALS, both on a 
psychological and physical level. It was also observed an improvement in caregivers 
psychological well-being, probably due to the improvement of both psychological 
(improvement in depression, anxiety and quality of life) and physical (decreases in 
pain, sleep disturbances, emotional lability and fasciculations) aspects perceived by 
patients.  
 
4.6 Conclusion 
 
To the best of our knowledge, this is the first report of a psychological intervention 
protocol on ALS patients. 
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Even if at a preliminary level, and despite the pilot study limitations, the findings 
provided an encouraging support for using hypnosis to manage some physical 
consequences of ALS and mainly to cope with its dramatic psychological 
implications for the patients and, indirectly, for their caregivers.  
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X-linked Spinal and Bulbar Muscular Atrophy 
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5.1 Definition 
 
X-linked Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy’s 
disease (after its initial description as a clinical entity in 1968) [1], is a rare, 
genetically inherited neuromuscular disorder characterized by dysfunction and loss 
of lower motor neurons (LMN) in the brainstem and spinal cord [1-2].  
The causative mutation in SBMA is the expansion of a CAG trinucleotide repeat, 
which encodes a polyglutamine (polyQ) tract in the androgen receptor [3]. 
Androgen receptor (AR) contains three polyQ tracts, of which one is polymorphic in 
length with an average length of approximately 21-25 residues; the other two are 
respectively composed of five and six glutamine residues [4]. 
Expansion of the first polyQ tract to greater than 37 residues causes disease and the 
longest expansion described to date in patients is 62 residues [5]. 
Since SBMA is X-chromosomal it affects only adult males. Females only show 
subclinical symptoms even if they are homozygous for the mutation [6]. 
 
5.2 Epidemiology 
 
Among the hereditary motor neuron diseases, Spinal and Bulbar Muscular Atrophy 
has one of the lowest prevalence, that is estimated to be 3.3/100,000 among male 
population  and the mean annual incidence was 0.19/100,000 among male population 
[7]. 
The onset of weakness is usually between 30 and 60 years of age. Postural tremor of 
the fingers is often observed prior to weakness.  
 
5.3 Clinical features  
 
Phenotypically, patients present amyotrophic, proximal or distal weakness and 
wasting of the facial, bulbar and limb muscles, occasional sensory disturbances, and 
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endocrine disturbances, such as androgen resistance, gynecomastia, elevated 
testosterone or progesterone, and reduced fertility [8]. 
Nowadays SBMA is described as a multisystem disease because neurologic deficits 
associated with SBMA are very similar to those of ALS. The main differences are 
the absence of upper motor neuron involvement in SBMA and the X-linked 
inheritance pattern. Patients with SBMA typically present progressive neuromuscular 
weakness that most commonly includes the bulbar muscles. Fasciculations are a 
prominent feature of both. Previously, distinction between these two disorders was 
difficult. Up to date, however, with genetic testing these can be distinguished with a 
certain grade of reliability [9]. The symptoms are slowly progressive in SBMA, and 
the susceptibility for aspiration pneumonia increases as bulbar paralysis develops. 
The most common cause of death is pneumonia [10]. 
SBMA is generally believed to be relatively benign compared to other life-ending 
and neurologically devastating forms of other motor neuron disorders [9].  
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6.1 Psychological and neuropsychological aspects of SBMA patients: an 
overview 
 
Spinal and bulbar muscular atrophy (SBMA or Kennedy’s disease) is an adult-onset 
hereditary neurodegenerative disorder, associated predominantly with a lower motor 
neuron syndrome and eventually endocrine and sensory disturbances. In contrast to 
other motor neuron diseases such as amyotrophic lateral sclerosis (ALS), the 
impairment of cognition in SBMA is poorly characterized. Recent studies highlight 
that fronto-temporal cognitive functions are impaired in SBMA patients, although at 
a subclinical level and not relevant to the patients’ everyday functioning. Thus, 
functional deficits in SBMA, which could indicate subtle frontal lobe dysfunction, 
are not confined to motor neurons but also affect extramotor networks [2-3]. 
From a clinical viewpoint, it is common for patients with SBMA to have particular 
psychological characteristics such as diffidence, marked emotional sensitivity and 
concentration problems. These observation generally seems to confirm that higher-
order frontotemporal functions could be particularly vulnerable in SBMA, as often 
see in ALS [1,4].  
 
6.2 Aim of study 
 
The aim of this research was to investigate the not well documented and mostly 
unknown neuropsychological and psychological profile of SBMA patients, focusing 
on cognitive functions and on Theory of Mind (ToM) abilities.  
The emerging literature suggests that social cognition abilities are subserved by a 
complex fronto-striatal network, likely with right hemispheric predominance [5]. An 
integral component of social signal processing is an extensively investigated 
phenomenon termed Theory of Mind (ToM) or mentalizing. 
ToM refers to the ability to attribute independent “mental states”, including 
knowledge, belief and motives to other individuals in order to understand and predict 
their behaviour [6]. 
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There are two subcomponents of ToM: 
- “cognitive ToM” refers to the ability to recognise that another individual may have 
knowledge and belief which are different from one’s own beliefs. It has been linked 
to the temporal-parietal junctions and dorsolateral prefrontal cortex [7-8];  
- “affective ToM” refers to ability to infer another person’s emotional state or how 
they are “feeling”. This subcomponents is largely subserved by the ventro-medial 
prefrontal cortex and the orbitofrontal cortex, particularly in the right emisphere [7-
9]. 
Although it has been shown that cognitive and affective ToM can de dissociated, 
everyday life social interactions often requires contributions from both 
subcomponents.  
 
6.3 Methods 
 
For this study were recruited 20 genetically proven SBMA patients (age range 41-74 
years) referred to Motor Neuron Disease Centre of Padua University Hospital and 18 
age/educational-matched controls (HCs, age range 41-71 years), all healthy males 
volunteers.  
Exclusion criteria for patients and HCs include: diagnosis of any king of dementia, 
history of previous neurological conditions that could affect cognition, depressive 
symptoms, psychiatric diseases, ongoing use of high-dose psychoactive medication.  
All patients underwent a neurological assessment before the neuropsychological and 
psychological assessment.  
Neuropsychological assessment, in accordance to the recent literature, included tests 
to evaluate:  
 
a. executive functions and attention 
- the Semantic Fluency Tests by semantic and phonemic categories [10-11],  
- the Trial Making Test (TMT) A e B [12]. 
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b. long-term and short-term memories 
- the Babcock Story immediate and delayed recall test [13]. 
- the Digit Span Forward and the Backward [13].  
 
c. ToM tasks 
- the Faux Pas Test [14-15],  
- the Reading the Mind in the Eyes Test [16].  
Healthy controls underwent the same neuropsychological battery.  
 
6.4 Data analysis 
 
All analyses were carried out with SPSS rel. 18.0. Non-parametric statistical analysis 
were preferred because they require few, if any, assumptions about the shapes of the 
underlying population distributions, and they are more robust for small samples [17-
18].  
 
6.5 Results 
 
The results of the neuropsychological assessment for the group of patients showed no 
significant impairment in executive function, attention or memory by comparison 
with the control group. However, a clear dissociation emerged between patient’s 
cognitive and affective empathy. Patients had distinctive deficits in mentalizing, as 
assessed with the Faux Pas Test, whilst affective empathy, assessed with the Reading 
the Mind in the Eyes test, appeared to be preserved.  
 
6.6 Conclusion  
 
To the best of our knowledge, this is the first study to investigate ToM in connection 
with neuropsychological functioning in SBMA patients. To sum up, in contrast with 
the previous literature, executive functioning seems to be apparently preserved in 
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patients with SBMA. Nevertheless, patients seem to have a specific dysfunction in 
the ability to interpret social situations by appropriately identifying other people’s 
intentions. The likely implications of subtle frontal lobe impairments and the 
influence of androgen insensitivity in these SBMA male patients seem to explain 
these findings. Subtle frontal lobe impairment could explain variable cognitive 
impairment and  the “cognitive” subcomponent of Theory of Mind (ToM)  could be 
compromised because it seems to involve several extra-frontal areas while, on the 
other hand, insensitivity to androgens could afford a sort of affective empathy 
advantage for males with SBMA, whose more affective subcomponents of ToM 
result consequently preserved.  
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